Join to view full profile
602 Indiana AveLubbock, TX 79415
Phone+1 806-775-8600
Fax+1 806-775-8602
Dr. Dcunha is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1995
Rutgers Health/Jersey City Medical CenterResidency, Internal Medicine, 1992- Rutgers Health/Jersey City Medical CenterInternship, Internal Medicine, 1989 - 1990
Topiwala National Medical CollegeClass of 1981
Certifications & Licensure
TX State Medical License 2003 - 2026
NY State Medical License 1999 - 2020
NM State Medical License 2004 - 2009
NJ State Medical License 1991 - 2007
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification PowerChart (Clinical), Cerner Corporation, 2016
- CMS Meaningful Use Stage 1 Certification P2 Sentinel, Cerner Corporation, 2016
- CMS Meaningful Use Stage 1 Certification PowerChart (CQM), Cerner Corporation, 2016
Publications & Presentations
PubMed
- 1 citationsGiant-cell tumor of bone with pathological evidence of blood vessel invasion.Shadi Khalil, Rachana Yendala, Nicholas D'Cunha, Fred Hardwicke, Mohamed Shanshal
Hematology/oncology and Stem Cell Therapy. 2017-09-01 - 61 citationsChimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.Jose A. Figueroa, Adair Reidy, Leonardo Mirandola, Kayley Trotter, Natallia Suvorava
International Reviews of Immunology. 2015-04-22 - 8 citationsReactive Thrombocytosis Associated with Acute Myocardial Infarction following STEMI with Percutaneous Coronary Intervention.Nat Dumrongmongcolgul, Charoen Mankongpaisarnrung, Grerk Sutamtewagul, Nattamol Hosiriluck, Timothy Chen
Case Reports in Cardiology. 2013-11-24
Abstracts/Posters
- Tolerability in Patients with Multiple Myeloma Treated with Daratumumab: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled TrialsNicholas D'Cunha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Updated Meta-Analysis of Randomized Controlled Trials to Evaluate the Incidence of Infection and Pneumonia in Patients with Multiple Myeloma Treated with DaratumumabNicholas D'Cunha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Daratumumab-Related Hematological Toxicities in Patients with Multiple Myeloma: A Combined Analysis of Five Phase III Randomized Controlled TrialsNicholas D'Cunha, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Other Languages
- Hindi, Urdu
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
